GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opthea Ltd (ASX:OPT) » Definitions » 3-Year RORE %

Opthea (ASX:OPT) 3-Year RORE % : 21.93% (As of Dec. 2023)


View and export this data going back to 1991. Start your Free Trial

What is Opthea 3-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Opthea's 3-Year RORE % for the quarter that ended in Dec. 2023 was 21.93%.

The industry rank for Opthea's 3-Year RORE % or its related term are showing as below:

ASX:OPT's 3-Year RORE % is ranked better than
83.33% of 1392 companies
in the Biotechnology industry
Industry Median: -5.96 vs ASX:OPT: 21.93

Opthea 3-Year RORE % Historical Data

The historical data trend for Opthea's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opthea 3-Year RORE % Chart

Opthea Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.12 -8.64 28.75 50.09 27.96

Opthea Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 33.57 50.09 38.85 27.96 21.93

Competitive Comparison of Opthea's 3-Year RORE %

For the Biotechnology subindustry, Opthea's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Opthea's 3-Year RORE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Opthea's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Opthea's 3-Year RORE % falls into.



Opthea 3-Year RORE % Calculation

Opthea's 3-Year RORE % for the quarter that ended in Dec. 2023 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -0.448--0.205 )/( -1.108-0 )
=-0.243/-1.108
=21.93 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2023 and 3-year before.


Opthea  (ASX:OPT) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Opthea 3-Year RORE % Related Terms

Thank you for viewing the detailed overview of Opthea's 3-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Opthea (ASX:OPT) Business Description

Traded in Other Exchanges
Address
650 Chapel Street, Level 4, Suite 0403, South Yarra, VIC, AUS, 3141
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused primarily on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.

Opthea (ASX:OPT) Headlines

From GuruFocus

Top 5 2nd Quarter Trades of Regal Partners Ltd

By GuruFocus Research GuruFocus Editor 09-09-2022

Opthea To Present at Upcoming Investor Conferences

By GuruFocusNews GuruFocusNews 06-20-2022

Opthea To Present at Upcoming Investor Conferences

By GuruFocusNews GuruFocusNews 07-10-2022

Opthea To Present at Upcoming Investor Conferences

By GuruFocusNews GuruFocusNews 06-30-2022

Opthea To Present at SVB Leerink Global Biopharma Conference

By Stock market mentor Stock market mentor 02-06-2023

Opthea To Present at Sequire Biotechnology Conference

By Stock market mentor Stock market mentor 01-30-2023